-
1
-
-
27244440324
-
Molecular genetics of acute lymphoblastic leukemia
-
DOI 10.1200/JCO.2005.05.047
-
Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005;23:6306-6315. (Pubitemid 46218840)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.26
, pp. 6306-6315
-
-
Armstrong, S.A.1
Look, A.T.2
-
2
-
-
33747144031
-
Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project
-
Coebergh JW, Reedijk AM, de Vries E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42: 2019-2036.
-
(2006)
Eur J Cancer
, vol.42
, pp. 2019-2036
-
-
Coebergh, J.W.1
Reedijk, A.M.2
De Vries, E.3
-
3
-
-
33748993099
-
Acute lymphoblastic leukemia
-
Pizzo PA, Poplack DG, editors. 5th edition. Philadelphia: Lippincott Williams and Wilkins
-
Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, 5th edition. Philadelphia: Lippincott Williams and Wilkins; 2006. pp. 538-590.
-
(2006)
Principles and Practice of Pediatric Oncology
, pp. 538-590
-
-
Margolin, J.F.1
Steuber, C.P.2
Poplack, D.G.3
-
4
-
-
0037672877
-
Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics
-
Kurzrock R, Kantarjian HM, Druker BJ, et al. Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-830. (Pubitemid 38124644)
-
(2003)
Annals of Internal Medicine
, vol.138
, Issue.10
, pp. 819-830
-
-
Kurzrock, R.1
Kantarjian, H.M.2
Druker, B.J.3
Talpaz, M.4
-
5
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
DOI 10.1038/nm0596-561
-
Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566. (Pubitemid 26151518)
-
(1996)
Nature Medicine
, vol.2
, Issue.5
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
Ohno, S.4
Segal, G.M.5
Fanning, S.6
Zimmermann, J.7
Lydon, N.B.8
-
6
-
-
20844452050
-
Imatinib mesylate (STI 571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study
-
Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI 571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-2660.
-
(2004)
Blood
, vol.104
, pp. 2655-2660
-
-
Champagne, M.A.1
Capdeville, R.2
Krailo, M.3
-
7
-
-
1642494654
-
Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion
-
DOI 10.1177/0091270003262101
-
Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Gleevec®) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-162. (Pubitemid 38114314)
-
(2004)
Journal of Clinical Pharmacology
, vol.44
, Issue.2
, pp. 158-162
-
-
Peng, B.1
Dutreix, C.2
Mehring, G.3
Hayes, M.J.4
Ben-Am, M.5
Seiberling, M.6
Pokorny, R.7
Cupdeville, R.8
Lloyd, P.9
-
8
-
-
24944581623
-
Metabolism and disposition of imatinib mesylate in healthy volunteers
-
DOI 10.1124/dmd.105.004283
-
Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503-1512. (Pubitemid 41323999)
-
(2005)
Drug Metabolism and Disposition
, vol.33
, Issue.10
, pp. 1503-1512
-
-
Gschwind, H.-P.1
Pfaar, U.2
Waldmeier, F.3
Zollinger, M.4
Sayer, C.5
Zbinden, P.6
Hayes, M.7
Pokorny, R.8
Seiberling, M.9
Ben-Am, M.10
Peng, B.11
Gross, G.12
-
9
-
-
58149214370
-
Population pharmacokinetics and pharmacogenetics of imatinib in children and adults
-
Petain A, Kattygnarath D, Azard J, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008;14:7102-7109.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7102-7109
-
-
Petain, A.1
Kattygnarath, D.2
Azard, J.3
-
10
-
-
34147202548
-
Phase 1 trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas
-
Pollack IF, Jakacki RI, Blaney SM, et al. Phase 1 trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas. Neuro-oncology 2007;9:145-160.
-
(2007)
Neuro-oncology
, vol.9
, pp. 145-160
-
-
Pollack, I.F.1
Jakacki, R.I.2
Blaney, S.M.3
-
11
-
-
37549041711
-
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group Study
-
Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group Study. Pediatr Blood Cancer 2008; 50:254-258.
-
(2008)
Pediatr Blood Cancer
, vol.50
, pp. 254-258
-
-
Bond, M.1
Bernstein, M.L.2
Pappo, A.3
-
12
-
-
0030428256
-
Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans
-
DOI 10.1007/BF02353475
-
Wilkinson GR. Cytochrome P450 3A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-490. (Pubitemid 27156933)
-
(1996)
Journal of Pharmacokinetics and Biopharmaceutics
, vol.24
, Issue.5
, pp. 475-490
-
-
Wilkinson, G.R.1
-
13
-
-
57249088703
-
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
-
Menon-Anderson D, Mondick JT, Jayaraman B, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 2009; 63:229-238.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 229-238
-
-
Menon-Anderson, D.1
Mondick, J.T.2
Jayaraman, B.3
-
14
-
-
0022626874
-
A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
-
Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415-421. (Pubitemid 16097805)
-
(1986)
Nature
, vol.320
, Issue.6061
, pp. 415-421
-
-
Besmer, P.1
Murphy, J.E.2
George, P.C.3
-
15
-
-
0023989811
-
Primary structure of c-kit relationship with the CSF-1/PDGF receptor kinase family oncogenic terminus
-
Qiu FH, Ray P, Brown K, et al. Primary structure of c-kit relationship with the CSF-1/PDGF receptor kinase family oncogenic terminus. EMBO J 1988;7:1003-1011.
-
(1988)
EMBO J
, vol.7
, pp. 1003-1011
-
-
Qiu, F.H.1
Ray, P.2
Brown, K.3
-
16
-
-
0034254249
-
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
-
Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932.
-
(2000)
Blood
, vol.96
, pp. 925-932
-
-
Heinrich, M.C.1
Griffith, D.J.2
Druker, B.J.3
-
17
-
-
0035421175
-
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis
-
Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI 571 through induction of apoptosis. Cancer Res 2001;61:5778-5783. (Pubitemid 32769094)
-
(2001)
Cancer Research
, vol.61
, Issue.15
, pp. 5778-5783
-
-
Sjoblom, T.1
Shimizu, A.2
O'Brien, K.P.3
Pietras, K.4
Dal Cin, P.5
Buchdunger, E.6
Dumanski, J.P.7
Ostman, A.8
Heldin, C.-H.9
-
18
-
-
0028968622
-
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylamidopyrimidine class
-
Buchdunger E, Zimmerman J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylamidopyrimidine class. Proc Nat Acad Sci USA 1995;92:2558-2562.
-
(1995)
Proc Nat Acad Sci USA
, vol.92
, pp. 2558-2562
-
-
Buchdunger, E.1
Zimmerman, J.2
Mett, H.3
-
19
-
-
0033816156
-
Abl protein-tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
-
Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:137-145.
-
(2000)
J Pharmacol Exp Ther
, vol.295
, pp. 137-145
-
-
Buchdunger, E.1
Cioffi, C.L.2
Law, N.3
-
20
-
-
0036209138
-
C-kit expression in pediatric solid tumors: A comparative immunohistochemical study
-
DOI 10.1097/00000478-200204000-00011
-
Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: A comparative immuohistochemical study. Am J Surg Pathol 2002;26:486-492. (Pubitemid 34280122)
-
(2002)
American Journal of Surgical Pathology
, vol.26
, Issue.4
, pp. 486-492
-
-
Smithey, B.E.1
Pappo, A.S.2
Hill, D.A.3
-
21
-
-
10744222923
-
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
-
DOI 10.1158/1078-0432.CCR-0778-03
-
Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751-761. (Pubitemid 38174013)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.2
, pp. 751-761
-
-
Gonzalez, I.1
Andreu, E.J.2
Panizo, A.3
Inoges, S.4
Fontalba, A.5
Fernandez-Luna, J.L.6
Gaboli, M.7
Sierrasesumaga, L.8
Martin-Algarra, S.9
Pardo, J.10
Prosper, F.11
De Alava, E.12
-
22
-
-
1042301962
-
Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor beta Tyrosine Kinase Receptors in Synovial Sarcoma
-
DOI 10.1158/1078-0432.CCR-03-0059
-
Tamborini E, Bonadiman L, Greco A, et al. Expression of ligand-activated KIT and platelet-derived growth factor beta tyrosine kinase receptor in synovial sarcoma. Clin Cancer Res 2004;10: 938-943. (Pubitemid 38198893)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.3
, pp. 938-943
-
-
Tamborini, E.1
Bonadiman, L.2
Greco, A.3
Gronchi, A.4
Riva, C.5
Bertulli, R.6
Casali, P.G.7
Pierotti, M.A.8
Pilotti, S.9
-
23
-
-
0028019224
-
Expression of stem cell factor and c-kit in human neuroblastoma
-
The Children's Cancer Group
-
Cohen PS, Chan JP, Lipunskaya M, et al. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 1994;84:3465-3472.
-
(1994)
Blood
, vol.84
, pp. 3465-3472
-
-
Cohen, P.S.1
Chan, J.P.2
Lipunskaya, M.3
-
24
-
-
5044234118
-
C-kit gene mutations in intracranial germinomas
-
Sakuma Y, Sakurai S, Oguni S, et al. C-kit gene mutations in intracranial germinomas. Cancer Sci 2004;95:716-720.
-
(2004)
Cancer Sci
, vol.95
, pp. 716-720
-
-
Sakuma, Y.1
Sakurai, S.2
Oguni, S.3
-
25
-
-
49649119001
-
Molecular characterisation of pediatric gastro-intestinal stromal tumors
-
Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterisation of pediatric gastro-intestinal stromal tumors. Clin Cancer Res 2008;14:3204-3215.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3204-3215
-
-
Agaram, N.P.1
Laquaglia, M.P.2
Ustun, B.3
-
26
-
-
0142040159
-
Expression of HER2 and C-KIT in naso-pharyngeal carcinoma: Implications for a new therapeutic approach
-
Bar-Sela G, Kuten A, Ben-Eliezer S, et al. Expression of HER2 and C-KIT in naso-pharyngeal carcinoma: Implications for a new therapeutic approach. Mod Pathol 2003;16:1035-1040.
-
(2003)
Mod Pathol
, vol.16
, pp. 1035-1040
-
-
Bar-Sela, G.1
Kuten, A.2
Ben-Eliezer, S.3
-
27
-
-
26944447953
-
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
-
Goemans BF, Zwaan Ch-M, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005;19:1536-1542.
-
(2005)
Leukemia
, vol.19
, pp. 1536-1542
-
-
Goemans, B.F.1
Zwaan, Ch.-M.2
Miller, M.3
-
28
-
-
0343628689
-
Platelet-derived growth factor AA and alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma
-
Sulzbacher I, Traxler M, Mosberger I, et al. Platelet-derived growth factor AA and alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000;13:632-637.
-
(2000)
Mod Pathol
, vol.13
, pp. 632-637
-
-
Sulzbacher, I.1
Traxler, M.2
Mosberger, I.3
-
29
-
-
0037258254
-
Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma
-
DOI 10.1097/01.MP.0000043522.76788.0A
-
Sulzbacher I, Birner P, Trieb K, et al. Expression of platelet derived growth factor AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003;16:66-71. (Pubitemid 36152688)
-
(2003)
Modern Pathology
, vol.16
, Issue.1
, pp. 66-71
-
-
Sulzbacher, I.1
Birner, P.2
Trieb, K.3
Traxler, M.4
Lang, S.5
Chott, A.6
-
30
-
-
43049095679
-
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
-
DOI 10.1002/cncr.23437
-
Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008;112: 2119-2129. (Pubitemid 351628620)
-
(2008)
Cancer
, vol.112
, Issue.10
, pp. 2119-2129
-
-
Kubo, T.1
Piperdi, S.2
Rosenblum, J.3
Antonescu, C.R.4
Chen, W.5
Kim, H.-S.6
Huvos, A.G.7
Sowers, R.8
Meyers, P.A.9
Healey, J.H.10
Gorlick, R.11
-
31
-
-
0026569415
-
Platelet derived growth factor receptor (beta subunit) immunoreactivity in soft tissue tumors
-
Palman C, Bowen-Pope DF, Brooks JJ. Platelet derived growth factor receptor (beta subunit) immunoreactivity in soft tissue tumors. Lab Invest 1992;66:108-115.
-
(1992)
Lab Invest
, vol.66
, pp. 108-115
-
-
Palman, C.1
Bowen-Pope, D.F.2
Brooks, J.J.3
-
32
-
-
0032995853
-
Intra-abdominal small round cell tumor: Immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors
-
Froberg K, Brown RE, Gayloard H, et al. Intra-abdominal small round cell tumor: Immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Ann Clin Lab Sci 1999;29:78-85.
-
(1999)
Ann Clin Lab Sci
, vol.29
, pp. 78-85
-
-
Froberg, K.1
Brown, R.E.2
Gayloard, H.3
-
33
-
-
0030699247
-
The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour
-
DOI 10.1038/ng1197-309
-
Lee SB, Kolquist KA, Nichols K, et al. The EWS-WTI translocation product induces PDGFA in desmoplastic small round cell tumors. Nat Genet 1997;17:309-313. (Pubitemid 27475994)
-
(1997)
Nature Genetics
, vol.17
, Issue.3
, pp. 309-313
-
-
Lee Bong, S.1
Kolquist, K.A.2
Nichols, K.3
Englert, C.4
Maheswaran, S.5
Ladanyi, M.6
Gerald, W.L.7
Haber, D.A.8
-
34
-
-
15444380819
-
PDGF-A, PDGFR beta, TGF beta 3 and bone morphogenic protein 4 in desmoplastic small round cell tumors with EWS-WTI gene fusion product and their role in stromal dysplasia: An immunohistochemical study
-
Zhang PJ, Goldblum JR, Pawel BR, et al. PDGF-A, PDGFR beta, TGF beta 3 and bone morphogenic protein 4 in desmoplastic small round cell tumors with EWS-WTI gene fusion product and their role in stromal dysplasia: An immunohistochemical study. Mod Pathol 2005;18:382-387.
-
(2005)
Mod Pathol
, vol.18
, pp. 382-387
-
-
Zhang, P.J.1
Goldblum, J.R.2
Pawel, B.R.3
-
35
-
-
0036645057
-
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors
-
Lokker NA, Sullivan CM, Hollenback SJ, et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002;62:3729-3735.
-
(2002)
Cancer Res
, vol.62
, pp. 3729-3735
-
-
Lokker, N.A.1
Sullivan, C.M.2
Hollenback, S.J.3
-
37
-
-
0037146220
-
Potential use of imatinib in Ewing's sarcoma: Evidence for in vitro and in vivo activity
-
Merchant MS, Woo CW, Mackall CL, et al. Potential use of imatinib in Ewing's sarcoma: Evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-1679.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1673-1679
-
-
Merchant, M.S.1
Woo, C.W.2
Mackall, C.L.3
-
38
-
-
33745212417
-
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor
-
DOI 10.1158/1078-0432.CCR-05-1778
-
Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor 1 receptor pathway inhibition by ADW 742, alone or in combination with imatinib, doxorubicin or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006; 12:3532-3540. (Pubitemid 43910901)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.11 I
, pp. 3532-3540
-
-
Martins, A.S.1
Mackintosh, C.2
Herrero Martin, D.3
Campos, M.4
Hernandez, T.5
Ordonez, J.-L.6
De Alava, E.7
-
39
-
-
0842323936
-
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression
-
Beppu K, Jaboine J, Merchant MS, et al. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96: 46-55. (Pubitemid 38180959)
-
(2004)
Journal of the National Cancer Institute
, vol.96
, Issue.1
, pp. 46-55
-
-
Beppu, K.1
Jaboine, J.2
Merchant, M.S.3
Mackall, C.L.4
Thiele, C.J.5
-
40
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
DOI 10.1056/NEJMoa022457
-
O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.11
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
Cornelissen, J.J.7
Fischer, T.8
Hochhaus, A.9
Hughes, T.10
Lechner, K.11
Nielsen, J.L.12
Rousselot, P.13
Reiffers, J.14
Saglio, G.15
Shepherd, J.16
Simonsson, B.17
Gratwohl, A.18
Goldman, J.M.19
Kantarjian, H.20
Taylor, K.21
Verhoef, G.22
Bolton, A.E.23
Capdeville, R.24
Druker, B.J.25
more..
-
41
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
DOI 10.1056/NEJM200104053441401
-
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 2001;344:1031-1037. (Pubitemid 32267972)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.J.3
Peng, B.4
Buchdunger, E.5
Ford, J.M.6
Lydon, N.B.7
Kantarjian, H.8
Capdeville, R.9
Ohno-Jones, S.10
Sawyers, C.L.11
-
42
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
DOI 10.1056/NEJM200104053441402
-
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344: 1038-1042. (Pubitemid 32267973)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
43
-
-
0037186915
-
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
-
DOI 10.1056/NEJMoa011573
-
Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chonic myelogenous leukemia. N Engl J Med 2002;346:645-652. (Pubitemid 34815868)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.9
, pp. 645-652
-
-
Kantarjian, H.1
Sawyers, C.2
Hochhaus, A.3
Guilhot, F.4
Schiffer, C.5
Gambacorti-Passerini, C.6
Niederwieser, D.7
Resta, D.8
Capdeville, R.9
Zoellner, U.10
Talpaz, M.11
Druker, B.12
-
44
-
-
0035992318
-
Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
-
Kantarjian H, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002;8:2167-2176. (Pubitemid 34753587)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.7
, pp. 2167-2176
-
-
Kantarjian, H.M.1
O'Brien, S.2
Cortes, J.E.3
Smith, T.L.4
Rios, M.B.5
Shan, J.6
Yang, Y.7
Giles, F.J.8
Thomas, D.A.9
Faderl, S.10
Garcia-Manero, G.11
Jeha, S.12
Wierda, W.13
Issa, J.-P.J.14
Kornblau, S.M.15
Keating, M.16
Resta, D.17
Capdeville, R.18
Talpaz, M.19
-
45
-
-
77953263334
-
Chronic eosinophilic leukemia (CEL) with FIPILI - PDGFR alpha re-arrangement (F/P): The response to imatinib (IM) is durable. A report of 33 patients with a follow-up of 30-92 months
-
abstract 3894
-
Rondoni M, Ottaviani E, Cilloni D, et al. Chronic eosinophilic leukemia (CEL) with FIPILI - PDGFR alpha re-arrangement (F/P): The response to imatinib (IM) is durable. A report of 33 patients with a follow-up of 30-92 months. Blood 2009;114:1498 (abstract 3894).
-
(2009)
Blood
, vol.114
, pp. 1498
-
-
Rondoni, M.1
Ottaviani, E.2
Cilloni, D.3
-
46
-
-
77950396947
-
Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) patients (pts): Confirmatory results at 18 months of part 1 of the Spirit phase III randomized trial of the French CML Group (F1-LMC)
-
abstract 340
-
Guilhot F, Preudhomme C, Guilhot J, et al. Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) patients (pts): Confirmatory results at 18 months of part 1 of the Spirit phase III randomized trial of the French CML Group (F1-LMC). Blood 2009;114:144 (abstract 340).
-
(2009)
Blood
, vol.114
, pp. 144
-
-
Guilhot, F.1
Preudhomme, C.2
Guilhot, J.3
-
47
-
-
77953241114
-
Randomised comparison of imatinib 800 mg versus imatinib 400 mg +/- IFN in newly diagnosed BCR/ABL positive chronic phase CML: Analysis of molecular remissions at 12 months; the German CML Study IV
-
abstract 339
-
Hehlmann R, Jung-Munkwitz S, Lauseker L, et al. Randomised comparison of imatinib 800 mg versus imatinib 400 mg +/- IFN in newly diagnosed BCR/ABL positive chronic phase CML: Analysis of molecular remissions at 12 months; the German CML Study IV. Blood 2009;114:143-144 (abstract 339).
-
(2009)
Blood
, vol.114
, pp. 143-144
-
-
Hehlmann, R.1
Jung-Munkwitz, S.2
Lauseker, L.3
-
48
-
-
77949704880
-
Discontinuation of imatinib therapy after achieving a molecular remission in chronic myeloid leukemia patients
-
abstract 859
-
Mahon F-X, Rea D, Guilhot F, et al. Discontinuation of imatinib therapy after achieving a molecular remission in chronic myeloid leukemia patients. Blood 2009;114:353 (abstract 859).
-
(2009)
Blood
, vol.114
, pp. 353
-
-
Mahon, F.-X.1
Rea, D.2
Guilhot, F.3
-
49
-
-
79955693266
-
Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients
-
abstract 3290
-
Bazeos A, Khorashad J, Mahon F-X, et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients. Blood 2009; 114:1274-1275 (abstract 3290).
-
(2009)
Blood
, vol.114
, pp. 1274-1275
-
-
Bazeos, A.1
Khorashad, J.2
Mahon, F.-X.3
-
50
-
-
77954799488
-
Update on imatinibresistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety and long-term outcomes
-
abstract 1129
-
Kantarjian HM, Giles FJ, Bhalla KN, et al. Update on imatinibresistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety and long-term outcomes. Blood 2009;114:464 (abstract 1129).
-
(2009)
Blood
, vol.114
, pp. 464
-
-
Kantarjian, H.M.1
Giles, F.J.2
Bhalla, K.N.3
-
51
-
-
77954779639
-
Dasatinib is well-tolerated and efficacious in imatinib-intolerant patients with chronic phase myeloid leukemia (CP-CML)
-
abstract 1128
-
Khoury HJ, Mauro MJ, Matloub Y, et al. Dasatinib is well-tolerated and efficacious in imatinib-intolerant patients with chronic phase myeloid leukemia (CP-CML). Blood 2009;114: 463-464 (abstract 1128).
-
(2009)
Blood
, vol.114
, pp. 463-464
-
-
Khoury, H.J.1
Mauro, M.J.2
Matloub, Y.3
-
52
-
-
77957089790
-
Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - Results of a multi-centre phase 2/3 study
-
abstract 861
-
Cortes-Franco J, Raghunadharao D, Parikh P, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multi-centre phase 2/3 study. Blood 2009;114:352-353 (abstract 861).
-
(2009)
Blood
, vol.114
, pp. 352-353
-
-
Cortes-Franco, J.1
Raghunadharao, D.2
Parikh, P.3
-
53
-
-
74849117346
-
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib
-
Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res 2010;34:143-147.
-
(2010)
Leuk Res
, vol.34
, pp. 143-147
-
-
Breccia, M.1
Palandri, F.2
Iori, A.P.3
-
54
-
-
75749095531
-
Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML)
-
Klyuchnikov E, Kroger N, Brummendorf TH, et al. Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML). Biol Blood Marrow Transpl 2010;16:301-310.
-
(2010)
Biol Blood Marrow Transpl
, vol.16
, pp. 301-310
-
-
Klyuchnikov, E.1
Kroger, N.2
Brummendorf, T.H.3
-
55
-
-
77449152581
-
Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: Results from the prospective trial CML - Paed 1
-
Suttorp M, Claviez A, Bader P, et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: Results from the prospective trial CML - paed 1. Klin Padiatr 2009;221:351-357.
-
(2009)
Klin Padiatr
, vol.221
, pp. 351-357
-
-
Suttorp, M.1
Claviez, A.2
Bader, P.3
-
56
-
-
77953279816
-
Chronic myeloid leukemia in pediatrics - First results from study CML-PAED II
-
abstract 342
-
Suttorp M, Thiede C, Tauer JT, et al. Chronic myeloid leukemia in pediatrics - First results from study CML-PAED II. Blood 2009;114:145 (abstract 342).
-
(2009)
Blood
, vol.114
, pp. 145
-
-
Suttorp, M.1
Thiede, C.2
Tauer, J.T.3
-
57
-
-
0038714747
-
Treating children with chronic myeloid leukemia in the imatinib era: A therapeutic dilemma?
-
Thornley I, Perentesis JP, Davies SM, et al. Treating children with chronic myeloid leukemia in the imatinib era: A therapeutic dilemma? Med Pediatr Oncol 2003;41:115-117.
-
(2003)
Med Pediatr Oncol
, vol.41
, pp. 115-117
-
-
Thornley, I.1
Perentesis, J.P.2
Davies, S.M.3
-
58
-
-
77953240842
-
-
accessed August 11, 2009
-
http://ctep.info.nih.gov/reporting/index.html (accessed August 11, 2009).
-
-
-
-
59
-
-
0036842322
-
Unexpected pleural effusions in 3 pediatric patients treated with STI 571
-
Goldsby R, Pulsipher M, Adams R, et al. Unexpected pleural effusions in 3 pediatric patients treated with STI 571. J Pediatr Hematol Oncol 2002;24:694-695.
-
(2002)
J Pediatr Hematol Oncol
, vol.24
, pp. 694-695
-
-
Goldsby, R.1
Pulsipher, M.2
Adams, R.3
-
60
-
-
31444450642
-
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
-
Millot M, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-192.
-
(2006)
Leukemia
, vol.20
, pp. 187-192
-
-
Millot, M.1
Guilhot, J.2
Nelken, B.3
-
61
-
-
70449711127
-
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study
-
Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 2009;27:5175-5181.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5175-5181
-
-
Schultz, K.R.1
Bowman, W.P.2
Aledo, A.3
-
62
-
-
4344597828
-
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
-
Cwynarski K, Laylor R, Macchiaruto E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004;18:1332-1339.
-
(2004)
Leukemia
, vol.18
, pp. 1332-1339
-
-
Cwynarski, K.1
Laylor, R.2
Macchiaruto, E.3
-
63
-
-
70149102515
-
Imatinib for refractory chronic graft-versus-host disease with fibrotic features
-
Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009;114:709-718.
-
(2009)
Blood
, vol.114
, pp. 709-718
-
-
Olivieri, A.1
Locatelli, F.2
Zecca, M.3
-
64
-
-
77953249020
-
Imatinib as salvage therapy for refractory cGVHD: The interim analysis of the prospective GITMO multicenter study Gruppo Italiano Trapianto di Midollo Osseo
-
abstract 3558
-
Olivieri A, Cimminiello M, Corredini P, et al. Imatinib as salvage therapy for refractory cGVHD: The interim analysis of the prospective GITMO multicenter study Gruppo Italiano Trapianto di Midollo Osseo. Blood 2009;114:1379-1380 (abstract 3558).
-
(2009)
Blood
, vol.114
, pp. 1379-1380
-
-
Olivieri, A.1
Cimminiello, M.2
Corredini, P.3
-
65
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
DOI 10.1056/NEJMoa055104
-
Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551. (Pubitemid 43882350)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.24
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
Bhalla, K.4
O'Brien, S.5
Wassmann, B.6
Tanaka, C.7
Manley, P.8
Rae, P.9
Mietlowski, W.10
Bochinski, K.11
Hochhaus, A.12
Griffin, J.D.13
Hoelzer, D.14
Albitar, M.15
Dugan, M.16
Cortes, J.17
Alland, L.18
Ottmann, O.G.19
-
66
-
-
34948829146
-
Dasatinib induces rapid hemtologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib. Interim results of phase 2 study
-
Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hemtologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib. Interim results of phase 2 study. Blood 2007;110:2309-2315.
-
(2007)
Blood
, vol.110
, pp. 2309-2315
-
-
Ottmann, O.1
Dombret, H.2
Martinelli, G.3
-
67
-
-
19944428353
-
Discovery of N- (2-chloro-6-methy1-phenyl)-2-6-(4-(2-hydroxyethl- piperazin-1-yl)-2-methlpyrimidin-4-ylamino)thiazole-5-carboxamide(BMS-354825), a dual Src/Abl Kinase inhibitor with potent anti-tumor activity in preclinical assays
-
Lombardo LJ, Lee FY, Chen P, et al. Discovery of N- (2-chloro-6-methy1- phenyl)-2-(6-(4-(2-hydroxyethl-piperazin-1-yl)-2-methlpyrimidin-4-ylamino) thiazole-5-carboxamide(BMS-354825), a dual Src/Abl Kinase inhibitor with potent anti-tumor activity in preclinical assays. J Med Chem 2004;47:6658-6661.
-
(2004)
J Med Chem
, vol.47
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
-
68
-
-
34548523623
-
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
-
DOI 10.1200/JCO.2007.12.0329
-
Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914. (Pubitemid 47477268)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.25
, pp. 3908-3914
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
O'Brien, S.3
Borthakur, G.4
Bruzzi, J.5
Munden, R.6
Cortes, J.7
-
69
-
-
0031947592
-
Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal
-
Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-1269. (Pubitemid 28221878)
-
(1998)
American Journal of Pathology
, vol.152
, Issue.5
, pp. 1259-1269
-
-
Kindblom, L.-G.1
Remotti, H.E.2
Aldenborg, F.3
Meis-Kindblom, J.M.4
-
70
-
-
0032602423
-
Mesenchymal tumors of the gastrointestinal tract: A paradise for acronyms (STUMP, GIST, GANT and now GIPACT), implications of C-kit in genesis and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases?
-
Chan JK. Mesenchymal tumors of the gastrointestinal tract: A paradise for acronyms (STUMP, GIST, GANT and now GIPACT), implications of C-kit in genesis and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anat Pathol 1999; 6:19-40.
-
(1999)
Adv Anat Pathol
, vol.6
, pp. 19-40
-
-
Chan, J.K.1
-
71
-
-
15644363454
-
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
-
DOI 10.1126/science.279.5350.577
-
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of C-kit in human gastro-intestinal stromal tumors. Science 1998;279:577-580. (Pubitemid 28067289)
-
(1998)
Science
, vol.279
, Issue.5350
, pp. 577-580
-
-
Hirota, S.1
Isozaki, K.2
Moriyama, Y.3
Hashimoto, K.4
Nishida, T.5
Ishiguro, S.6
Kawano, K.7
Hanada, M.8
Kurata, A.9
Takeda, M.10
Tunio, G.M.11
Matsuzawa, Y.12
Kanakura, Y.13
Shinomura, Y.14
Kitamura, Y.15
-
72
-
-
0242670019
-
PDGFRA activating mutations in gastrointestinal stromal tumors
-
Heinrich MC, Corless CL, Duensing A, et al.PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299: 708-710.
-
(2003)
Science
, vol.299
, pp. 708-710
-
-
Heinrich, M.C.1
Corless, C.L.2
Duensing, A.3
-
73
-
-
0642368571
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
-
Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4342-4349
-
-
Heinrich, M.C.1
Corless, C.L.2
Demetri, G.D.3
-
74
-
-
3042536213
-
Pediatric gastrointestinal stromal tumors and leiomyosarcoma. The St. Jude Children's Research Hospital experience and a review of the literature
-
Cypriano MS, Jenkins JJ, Pappo AS, et al. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. The St. Jude Children's Research Hospital experience and a review of the literature. Cancer 2004;101:39-50.
-
(2004)
Cancer
, vol.101
, pp. 39-50
-
-
Cypriano, M.S.1
Jenkins, J.J.2
Pappo, A.S.3
-
75
-
-
20944442418
-
Gastrointestinal stromal tumors in children and young adults. A clinicopathologic, molecular and genomic study of 15 cases and review of the literature
-
Prakash S, Sarran L, Socci N, et al. Gastrointestinal stromal tumors in children and young adults. A clinicopathologic, molecular and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 2005;27:179-187.
-
(2005)
J Pediatr Hematol Oncol
, vol.27
, pp. 179-187
-
-
Prakash, S.1
Sarran, L.2
Socci, N.3
-
76
-
-
25444494428
-
Gastrointestinal stromal tumors of the stomach in children and young adults: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature
-
Meittinen M, Lasota S, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005;29:1373-1381.
-
(2005)
Am J Surg Pathol
, vol.29
, pp. 1373-1381
-
-
Meittinen, M.1
Lasota, S.2
Sobin, L.H.3
-
77
-
-
0017736213
-
The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma
-
Carney JA, Sheps SG, Go VLW, et al. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977;296:1517-1518.
-
(1977)
N Engl J Med
, vol.296
, pp. 1517-1518
-
-
Carney, J.A.1
Sheps, S.G.2
Go, V.L.W.3
-
78
-
-
35148813515
-
Pediatric KIT - Wild-type and platelet-derived growth factor receptor - Wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors
-
Janeway KA, Liegl B, Harlow A, et al. Pediatric KIT - Wild-type and platelet-derived growth factor receptor - Wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007;67:9084-9088.
-
(2007)
Cancer Res
, vol.67
, pp. 9084-9088
-
-
Janeway, K.A.1
Liegl, B.2
Harlow, A.3
-
79
-
-
56749156604
-
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastro-intestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
-
Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastro-intestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:626-632.
-
(2008)
J Clin Oncol
, vol.26
, pp. 626-632
-
-
Heinrich, M.C.1
Owzar, K.2
Corless, C.L.3
-
80
-
-
39149127634
-
Phase III randomized intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
-
Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632.
-
(2008)
J Clin Oncol
, vol.26
, pp. 626-632
-
-
Blanke, C.D.1
Rankin, C.2
Demetri, G.D.3
-
81
-
-
24944529613
-
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors
-
A European Organisation for Research and Treatment of Cancer - Italian Sarcoma Group - Australasian Gastrointestinal Trials Group Study
-
Van Glabbeke M, Verweij J, Cashli PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors. A European Organisation for Research and Treatment of Cancer - Italian Sarcoma Group - Australasian Gastrointestinal Trials Group Study. J Clin Oncol 2005;23:5795-5804.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5795-5804
-
-
Van Glabbeke, M.1
Verweij, J.2
Cashli, P.G.3
-
82
-
-
67650472798
-
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
-
Janeway KA, Albritton KH,Van Den Abbeele AD, et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 2009;52:767-771.
-
(2009)
Pediatr Blood Cancer
, vol.52
, pp. 767-771
-
-
Janeway, K.A.1
Albritton, K.H.2
Van Den Abbeele, A.D.3
-
83
-
-
0242610826
-
Gleevec-mediated inhibition of Rad 51 expression and enhancement of tumor cell radio-sensitivity
-
Russell J, Brady K, Burgan W, et al. Gleevec-mediated inhibition of Rad 51 expression and enhancement of tumor cell radio-sensitivity. Cancer Res 2003;63:7377-7383.
-
(2003)
Cancer Res
, vol.63
, pp. 7377-7383
-
-
Russell, J.1
Brady, K.2
Burgan, W.3
-
84
-
-
68749098341
-
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumors
-
Baruchel S, Sharp JR, Bartels U, et al. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumors. Eur J Cancer 2009;45:2352-2359.
-
(2009)
Eur J Cancer
, vol.45
, pp. 2352-2359
-
-
Baruchel, S.1
Sharp, J.R.2
Bartels, U.3
-
85
-
-
0036399992
-
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebro-spinal fluid
-
Takayama N, Sato N, O'Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebro-spinal fluid. Br J Haematol 2002;119:106-108.
-
(2002)
Br J Haematol
, vol.119
, pp. 106-108
-
-
Takayama, N.1
Sato, N.2
O'Brien, S.G.3
-
86
-
-
2542439701
-
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid
-
Bornhauser M, Jenke A, Freiberg-Richter J, et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 2004;83:401-402.
-
(2004)
Ann Hematol
, vol.83
, pp. 401-402
-
-
Bornhauser, M.1
Jenke, A.2
Freiberg-Richter, J.3
-
87
-
-
51649111035
-
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
-
Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-1012.
-
(2008)
Blood
, vol.112
, pp. 1005-1012
-
-
Porkka, K.1
Koskenvesa, P.2
Lundan, T.3
-
88
-
-
68949170337
-
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium
-
Geoerger B, Morland B, Ndiaye A, et al. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer 2009;45:2342-2351.
-
(2009)
Eur J Cancer
, vol.45
, pp. 2342-2351
-
-
Geoerger, B.1
Morland, B.2
Ndiaye, A.3
-
89
-
-
33748068096
-
Dermatofibrosarcoma protuberans: A surgical disease with a molecular savior
-
McArthur GA. Dermatofibrosarcoma protuberans: A surgical disease with a molecular savior. Curr Opin Oncol 2006;18:341-346.
-
(2006)
Curr Opin Oncol
, vol.18
, pp. 341-346
-
-
McArthur, G.A.1
-
90
-
-
18144401652
-
Imatinib mesylate: An attractive alternative in young children with large surgically challenging dermatofibrosarcoma protuberans
-
Price VE, Fletcher JA, Zelenska M, et al. Imatinib mesylate: An attractive alternative in young children with large surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005;44:511-515.
-
(2005)
Pediatr Blood Cancer
, vol.44
, pp. 511-515
-
-
Price, V.E.1
Fletcher, J.A.2
Zelenska, M.3
-
91
-
-
67650799353
-
Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans
-
Han A, Chen EH, Niedt G, et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009;145: 792-796.
-
(2009)
Arch Dermatol
, vol.145
, pp. 792-796
-
-
Han, A.1
Chen, E.H.2
Niedt, G.3
-
92
-
-
0037380382
-
Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels and bone marrow pathology
-
Brockow K, Akin C, Huber M, et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels and bone marrow pathology. J Am Acad Dermatol 2003;48:508-516.
-
(2003)
J Am Acad Dermatol
, vol.48
, pp. 508-516
-
-
Brockow, K.1
Akin, C.2
Huber, M.3
-
93
-
-
33749368009
-
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
-
Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372.
-
(2006)
Blood
, vol.108
, pp. 2366-2372
-
-
Garcia-Montero, A.C.1
Jara-Acevedo, M.2
Teodosio, C.3
-
94
-
-
68649118339
-
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
-
Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481-1484.
-
(2009)
Leuk Res
, vol.33
, pp. 1481-1484
-
-
Vega-Ruiz, A.1
Cortes, J.E.2
Sever, M.3
-
95
-
-
33745863150
-
Imatinib mesylate in the treatment of systemic mastocytosis. A Phase II trial
-
Droogendijk HJ, Kluin Nelemans HJC, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis. A Phase II trial. Cancer 2006;107:345-351.
-
(2006)
Cancer
, vol.107
, pp. 345-351
-
-
Droogendijk, H.J.1
Kluin Nelemans, H.J.C.2
Van Doormaal, J.J.3
-
96
-
-
52649177664
-
Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2 year old boy carrying a somatic KIT mutation
-
Hoffman KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2 year old boy carrying a somatic KIT mutation. Blood 2008;112:1655-1657.
-
(2008)
Blood
, vol.112
, pp. 1655-1657
-
-
Hoffman, K.M.1
Moser, A.2
Lohse, P.3
-
97
-
-
78650667444
-
Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CP): Results of the French national phase IV trial
-
abstract 863
-
Millot F, Baruchel A, Guilhot J, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CP): Results of the French national phase IV trial. Blood 2009; 114:356 (abstract 863).
-
(2009)
Blood
, vol.114
, pp. 356
-
-
Millot, F.1
Baruchel, A.2
Guilhot, J.3
-
98
-
-
68049137764
-
Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib
-
Schmid H, Jaeger BAS, Lohse J, et al. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009; 94:1177-1179.
-
(2009)
Haematologica
, vol.94
, pp. 1177-1179
-
-
Schmid, H.1
Jaeger, B.A.S.2
Lohse, J.3
-
99
-
-
46949090042
-
Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty
-
Mariani F, Giona F, Basciani F, et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372:111-112.
-
(2008)
Lancet
, vol.372
, pp. 111-112
-
-
Mariani, F.1
Giona, F.2
Basciani, F.3
-
100
-
-
67349264054
-
Growth deceleration in a girl treated with imatinib
-
Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009;89:251-252.
-
(2009)
Int J Hematol
, vol.89
, pp. 251-252
-
-
Kimoto, T.1
Inoue, M.2
Kawa, K.3
-
101
-
-
70450277310
-
Imatinib mesylate causes growth plate closure in vivo
-
Vandyke K, Dewar AL, Fitter S, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009;23:2155-2159.
-
(2009)
Leukemia
, vol.23
, pp. 2155-2159
-
-
Vandyke, K.1
Dewar, A.L.2
Fitter, S.3
-
102
-
-
10744230733
-
Gynaecomastia in men with chronic myeloid leukemia after imatinib
-
Gambacorti-Passerini C, Tomaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukemia after imatinib. Lancet 2003;361:1954-1956.
-
(2003)
Lancet
, vol.361
, pp. 1954-1956
-
-
Gambacorti-Passerini, C.1
Tomaghi, L.2
Cavagnini, F.3
-
103
-
-
33646482407
-
Altered bone and mineral metabolism in patients receiving imatinib mesylate
-
Berman E, Nicolaides M, Malo RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-2013.
-
(2006)
N Engl J Med
, vol.354
, pp. 2006-2013
-
-
Berman, E.1
Nicolaides, M.2
Malo, R.G.3
-
104
-
-
46849094125
-
Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia
-
Jönsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008;93:1101-1103.
-
(2008)
Haematologica
, vol.93
, pp. 1101-1103
-
-
Jönsson, S.1
Olsson, B.2
Ohlsson, C.3
-
105
-
-
41949120243
-
Long-term imatinib therapy promotes bone formation in CML patients
-
Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111: 2538-2547.
-
(2008)
Blood
, vol.111
, pp. 2538-2547
-
-
Fitter, S.1
Dewar, A.L.2
Kostakis, P.3
-
106
-
-
33947528811
-
Osteopenia in children with cancer - The fragility of success
-
Sala A, Barr RD. Osteopenia in children with cancer - The fragility of success. Cancer 2007;109:1420-1431.
-
(2007)
Cancer
, vol.109
, pp. 1420-1431
-
-
Sala, A.1
Barr, R.D.2
-
107
-
-
77953279301
-
Hypophosphatemia during imatinib treatment of newly diagnosed chronic myeloid leukemia patients is associated with better response
-
abstract 1121
-
Casado LF, Massague I, Giraldo P, et al. Hypophosphatemia during imatinib treatment of newly diagnosed chronic myeloid leukemia patients is associated with better response. Blood; 114:459-460 (abstract 1121).
-
Blood
, vol.114
, pp. 459-460
-
-
Casado, L.F.1
Massague, I.2
Giraldo, P.3
-
108
-
-
77953248491
-
Imatinib long term effects (ILTE) study: An international study to evaluate long-term effects in CML patients
-
abstract 2199
-
Kim D-W, Antolini L, Mahon F-X, et al. Imatinib long term effects (ILTE) study: An international study to evaluate long-term effects in CML patients. Blood 2009;114:865-866 (abstract 2199).
-
(2009)
Blood
, vol.114
, pp. 865-866
-
-
Kim, D.-W.1
Antolini, L.2
Mahon, F.-X.3
-
109
-
-
77953243974
-
Imatinib mesylate induced cardiotoxicity: A cardiac progenitor cell disease?
-
abstract 2200
-
Prezioso L, Galaverna F, Tanzi S, et al. Imatinib mesylate induced cardiotoxicity: A cardiac progenitor cell disease? Blood 2009; 114:866 (abstract 2200).
-
(2009)
Blood
, vol.114
, pp. 866
-
-
Prezioso, L.1
Galaverna, F.2
Tanzi, S.3
-
110
-
-
33947254922
-
Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: A study of 98 cases
-
Funke VAM, Medeiro CR, Lima DH, et al. Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: A study of 98 cases. Rev Bras Hematol Hemoter 2005;27:159-165.
-
(2005)
Rev Bras Hematol Hemoter
, vol.27
, pp. 159-165
-
-
Funke, V.A.M.1
Medeiro, C.R.2
Lima, D.H.3
-
111
-
-
33947245976
-
Treatment of chronic myeloid leukemia in the imatinib era. Perspective from a developing country
-
Aziz Z, Iqbal J, Akram M, et al. Treatment of chronic myeloid leukemia in the imatinib era. Perspective from a developing country. Cancer 2007;109:1138-1145.
-
(2007)
Cancer
, vol.109
, pp. 1138-1145
-
-
Aziz, Z.1
Iqbal, J.2
Akram, M.3
-
112
-
-
39749097125
-
Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country
-
Rajappa S,Varadpande L, Paul T, et al. Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. Leuk Lymphoma 2008;49:554-558.
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 554-558
-
-
Rajappa, S.1
Varadpande, L.2
Paul, T.3
-
113
-
-
47549110816
-
Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKls?
-
Ruiz-Arguelles GJ, Tarin-Arzaga LC, Gonzalez-Carillo ML, et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKls? Bone Marrow Transpl 2008;42:23-28.
-
(2008)
Bone Marrow Transpl
, vol.42
, pp. 23-28
-
-
Ruiz-Arguelles, G.J.1
Tarin-Arzaga, L.C.2
Gonzalez-Carillo, M.L.3
-
114
-
-
67449123241
-
Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population
-
Zhao Y, Liu L, Wang Y, et al. Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol 2009;89:445-451.
-
(2009)
Int J Hematol
, vol.89
, pp. 445-451
-
-
Zhao, Y.1
Liu, L.2
Wang, Y.3
-
115
-
-
34447646300
-
European leukemia net: Chronic myeloid leukemia
-
Helmann R, Hochhaus A, Baccarani M. European leukemia net: Chronic myeloid leukemia. Lancet 2007;370:342-350.
-
(2007)
Lancet
, vol.370
, pp. 342-350
-
-
Helmann, R.1
Hochhaus, A.2
Baccarani, M.3
-
116
-
-
67650481560
-
Hits and misses in targeting pediatric cancers
-
Bernstein ML. Hits and misses in targeting pediatric cancers. Pediatr Blood Cancer 2009;52:751-752.
-
(2009)
Pediatr Blood Cancer
, vol.52
, pp. 751-752
-
-
Bernstein, M.L.1
|